An intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986231
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
BMS-986231
Covance Clinical Research Unit
Madison, Wisconsin, United States
Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC[0-T])
Measured by plasma concentrations
Time frame: Up to 8 days
Percent of Total Radioactivity Recovered in All Excreta (% total)
Measured by plasma urine, feces, and vomit (if applicable) volumes and radioactivity counts
Time frame: Up to 8 days
Half-Life (T-HALF)
Measured by plasma concentrations
Time frame: Up to 8 days
Total Body Clearance (CLT)
Measured by plasma concentrations
Time frame: Up to 8 days
Volume of Distribution during Terminal Elimination Phase (Vz/F)
Measured by plasma concentrations
Time frame: Up to 8 days
Time to Maximum Observed Concentration (Tmax)
Measured by plasma concentrations
Time frame: Up to 8 days
Incidence of adverse events (AEs)
Measured by investigator assessment
Time frame: Up to 8 days
Results of electrocardiogram tests (ECGs)
Measured by investigator assessment
Time frame: Up to 8 days
Results of vital sign measurements
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Measured by investigator assessment
Time frame: Up to 8 days
Results of clinical laboratory tests
Measured by investigator assessment
Time frame: Up to 8 days